|
07-15-2010, 02:21 PM
|
#1
|
Senior Member
Join Date: Sep 2005
Location: Alaska
Posts: 2,018
|
Gene C35 That Causes HER2 Breast Cancer To Spread Raises Hope For New Treatment
__________________
Dx 2002 age 51
bc for granny, aunt, cousin, sister, mother.
ER+/PR+/HER2+++, grade 3
IDC 1.9 cm, some DCIS, Stage 1, Grade 3
Lumpectomy, CAFx6 (no blood boosters), IMRT rads, 1 3/4 yr tamoxifen
Rads necrosis
BRCA 1 & 2 negative
Trials: Early detection OVCA; 2004 low-dose testosterone for bc survivors
Diet: Primarily vegetarian organic; metformin (no diabetes), vitamin D3
Exercise: 7 days a week, 1 hr/day
No trastuzumab, no taxane, no AI
NED
|
|
|
07-15-2010, 06:06 PM
|
#2
|
Senior Member
Join Date: May 2008
Location: Hershey, PA. Live The Sweet Life!
Posts: 2,005
|
Re: Gene C35 That Causes HER2 Breast Cancer To Spread Raises Hope For New Treatment
Terrific news!
__________________
Smile On!
Laurel
Dx'd w/multifocal DCIS/IDS 3/08
7mm invasive component
Partial mast. 5/08
Stage 1b, ER 80%, PR 90%, HER-2 6.9 on FISH
0/5 nodes
4 AC, 4 TH finished 9/08
Herceptin every 3 weeks. Finished 7/09
Tamoxifen 10/08. Switched to Femara 8/09
Bilat SPM w/reconstruction 10/08
Clinical Trial w/Clondronate 12/08
Stopped Clondronate--too hard on my gizzard!
Switched back to Tamoxifen due to tendon pain from Femara
15 Years NED
I think I just might hang around awhile....
|
|
|
07-15-2010, 07:40 PM
|
#3
|
Senior Member
Join Date: Jan 2008
Location: "Love never fails."
Posts: 5,808
|
Re: Gene C35 That Causes HER2 Breast Cancer To Spread Raises Hope For New Treatment
Great!
I want to be the genea pig when the drug for gene C35 is ready.
__________________
Jackie07
http://www.kevinmd.com/blog/2011/06/doctors-letter-patient-newly-diagnosed-cancer.html
http://www.asco.org/ASCOv2/MultiMedi...=114&trackID=2
NICU 4.4 LB
Erythema Nodosum 85
Life-long Central Neurocytoma 4x5x6.5 cm 23 hrs 62090 semi-coma 10 d PT OT ST 30 d
3 Infertility tmts 99 > 3 u. fibroids > Pills
CN 3 GKRS 52301
IDC 1.2 cm Her2 +++ ER 5% R. Lmptmy SLNB+1 71703 6 FEC 33 R Tamoxifen
Recc IIB 2.5 cm Bi-L Mast 61407 2/9 nds PET
6 TCH Cellulitis - Lymphedema - compression sleeve & glove
H w x 4 MUGA 51 D, J 49 M
Diastasis recti
Tamoxifen B. scan
Irrtbl bowel 1'09
Colonoscopy 313
BRCA1 V1247I
hptc hemangioma
Vertigo
GI - > yogurt
hysterectomy/oophorectomy 011410
Exemestane 25 mg tab 102912 ~ 101016 stopped due to r. hip/l.thigh pain after long walk
DEXA 1/13
1-2016 lesions in liver largest 9mm & 1.3 cm onco. says not cancer.
3-11 Appendectomy - visually O.K., a lot of puss. Final path result - not cancer.
Start Vitamin D3 and Calcium supplement (600mg x2)
10-10 Stopped Exemestane due to r. hip/l.thigh pain OKed by Onco 11-08-2016
7-23-2018 9 mm groundglass nodule within the right lower lobe with indolent behavior. Due to possible adenocarcinoma, Recommend annual surveilence.
7-10-2019 CT to check lung nodule.
1-10-2020 8mm stable nodule on R Lung, two 6mm new ones on L Lung, a possible lymph node involvement in inter fissule.
"I WANT TO BE AN OUTRAGEOUS OLD WOMAN WHO NEVER GETS CALLED AN OLD LADY. I WANT TO GET SHARP EDGED & EARTH COLORED, TILL I FADE AWAY FROM PURE JOY." Irene from Tampa
Advocacy is a passion .. not a pastime - Joe
|
|
|
07-15-2010, 10:38 PM
|
#4
|
Senior Member
Join Date: Feb 2008
Location: South East Wisconsin
Posts: 3,431
|
Re: Gene C35 That Causes HER2 Breast Cancer To Spread Raises Hope For New Treatment
|
|
|
07-19-2010, 01:20 PM
|
#5
|
Senior Member
Join Date: Aug 2006
Location: Pennsylvania
Posts: 1,080
|
Re: Gene C35 That Causes HER2 Breast Cancer To Spread Raises Hope For New Treatment
What they would be looking for is to see if you have the Her2 protein (the wild type verson c35 or Syk). It may be able to tell you whether or not your cells are potentially susceptible to this mechanism of attack. However, they would not be able to tell you if the chemicals BAY61-3606 or piceatannol will work for your individual cancer cells. It is still a "trial-and-error" approach as conventional chemotherapy is.
BAY61-3606 may kill cells containing a normal but overactive Her2 molecule, but piceatannol may have little effect on the mutant signal, because it strikes at a different part of the Her2 molecule. It involves a normal, not mutant, Her2 molecule. Or, vice versa.
While those with Her2 mutations may benefit from BAY61-3606, others without Her2 mutations may benefit from piceatannol. In this setting, to inhibit the mutant receptor, you need to inhibit the domain of the Her2 molecule that lies "within" the cell, as opposed to the domain that lies "outside" the cell.
What is still not understood by purveyors of the Cancer Genome Project is that the original Human Genome Project dealt with a homogeneous population of normal diploid cells. This is different from primary tumors, which are heterogeneous and have a genomic signature unique to each and every patient.
Sequencing the genome of cancer cells is explicitly based upon the assumption that the pathways - network of genes - of tumor cells can be known in sufficient detail to control cancer. Each cancer cell can be different and the cancer cells that are present change and evolve with time.
But the research will hopefully yield a new targeted treatment in the long term. Such knowledge can help to identify targets for new drug treatments.
Source: Cell Function Analysis
|
|
|
Posting Rules
|
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
HTML code is On
|
|
|
All times are GMT -7. The time now is 07:17 PM.
|